

Mojca Jensterle Sever

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6636061/publications.pdf>

Version: 2024-02-01

54
papers

1,325
citations

331670

21
h-index

377865

34
g-index

54
all docs

54
docs citations

54
times ranked

1469
citing authors

#	ARTICLE	IF	CITATIONS
1	Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1264.	4.1	60
2	Clinical Applicability of Patient- and Clinician-Reported Outcome Tools in the Management of Patients with Acromegaly. <i>Endocrine Practice</i> , 2022, , .	2.1	3
3	Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review. <i>Advances in Therapy</i> , 2022, 39, 2452-2467.	2.9	58
4	The Relationship between COVID-19 and Hypothalamicâ€Pituitaryâ€Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excessâ€The CAPISCO International Expert Panel. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7326.	4.1	30
5	The Endometrial Transcriptome of Metabolic and Inflammatory Pathways During the Window of Implantation Is Deranged in Infertile Obese Polycystic Ovarian Syndrome Women. <i>Metabolic Syndrome and Related Disorders</i> , 2022, 20, 384-394.	1.3	4
6	Glucagon-like peptide-1, a matter of taste?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 763-775.	5.7	8
7	Glucagon-Like Peptide 1 and Taste Perception: From Molecular Mechanisms to Potential Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 902.	4.1	11
8	Factors associated with degraded trabecular bone score in heart transplant recipients. <i>Clinical Transplantation</i> , 2021, 35, e14274.	1.6	2
9	Effects of metformin withdrawal after long and short term treatment in PCOS: observational longitudinal study. <i>Diabetology and Metabolic Syndrome</i> , 2021, 13, 43.	2.7	2
10	A rare metanephrineâ€predominant secretion phenotype of paraganglioma challenged an interpretation of imaging localization. <i>Endocrine</i> , 2021, 74, 432-434.	2.3	0
11	Natural history of nonfunctioning adrenal incidentalomas: a 10-year longitudinal follow-up study. <i>Endocrine Connections</i> , 2021, 10, 637-645.	1.9	5
12	Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial. <i>Trials</i> , 2021, 22, 464.	1.6	4
13	Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study. <i>Diabetes Research and Clinical Practice</i> , 2021, 178, 108935.	2.8	9
14	Treatment of osteoporosis with teriparatide: The Slovenian experience. <i>Open Medicine (Poland)</i> , 2021, 16, 1544-1551.	1.3	2
15	Glucose transporter 4 mRNA expression in subcutaneous adipose tissue of women with PCOS remains unchanged despite metformin withdrawal: is there a cellular metabolic treatment legacy effect?. <i>Endocrine</i> , 2021, , 1.	2.3	3
16	¹⁸ F-Fluorocholine PET/CT in Primary Hyperparathyroidism: Superior Diagnostic Performance to Conventional Scintigraphic Imaging for Localization of Hyperfunctioning Parathyroid Glands. <i>Journal of Nuclear Medicine</i> , 2020, 61, 577-583.	5.0	50
17	Adrenal failure and antiphospholipid syndrome. <i>Journal of International Medical Research</i> , 2020, 48, 030006052090365.	1.0	5
18	The prevalence and characteristics of non-functioning and autonomous cortisol secreting adrenal incidentaloma after patientsâ€™ stratification by body mass index and age. <i>BMC Endocrine Disorders</i> , 2020, 20, 118.	2.2	12

#	ARTICLE	IF	CITATIONS
19	Genetic Variability in Antioxidative and Inflammatory Pathways Modifies the Risk for PCOS and Influences Metabolic Profile of the Syndrome. <i>Metabolites</i> , 2020, 10, 439.	2.9	16
20	Periprostatic paraganglioma causing occult Cushing's syndrome. <i>Endocrine</i> , 2020, 69, 461-463.	2.3	0
21	Prevalence of Endocrine and Metabolic Comorbidities in a National Cohort of Patients with Craniopharyngioma. <i>Hormone Research in Paediatrics</i> , 2020, 93, 46-57.	1.8	17
22	Endocrine disorders after heart transplantation: national cohort study. <i>BMC Endocrine Disorders</i> , 2020, 20, 54.	2.2	7
23	Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort. <i>Endocrine Connections</i> , 2020, 9, 44-54.	1.9	18
24	Adrenal vein sampling for primary aldosteronism: a 15-year national referral center experience. <i>Radiology and Oncology</i> , 2020, 54, 409-418.	1.7	9
25	MON-LB57 Impact of Imputation Method and Response Cutoffs on Results From the Phase 3 OPTIMAL Study of Oral Octreotide Capsules in Adult Patients With Acromegaly. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	0
26	The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. <i>Human Reproduction Update</i> , 2019, 25, 504-517.	10.8	34
27	Individualization of Custom Compounded Hormone Therapy in a Patient with Chemotherapy Induced Premature Ovarian Insufficiency and Impaired Liver Function – Case Report. <i>Acta Clinica Croatica</i> , 2019, 58, 167-172.	0.2	1
28	MON-220 Androstendione Affects Endometrial Gene Expression Profile During Window of Implantation in Obese Infertile Women with PCOS. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	1
29	Advances in the management of craniopharyngioma in children and adults. <i>Radiology and Oncology</i> , 2019, 53, 388-396.	1.7	42
30	SUN-221 Effects of Liraglutide on Obesity-Associated Functional Hypogonadism in Men: A Randomized, Testosterone Replacement Treatment-Controlled Study. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0
31	Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. <i>European Journal of Endocrinology</i> , 2018, 179, 1-11.	3.7	127
32	Dpp4 Inhibitor Sitagliptin As A Potential Treatment Option In Metformin-Intolerant Obese Women With Polycystic Ovary Syndrome: A Pilot Randomized Study. <i>Endocrine Practice</i> , 2018, 24, 69-77.	2.1	33
33	Incretin System: New Pharmacological Target in Obese Women with Polycystic Ovary Syndrome. , 2018, , .		1
34	SLC6A4/5HTTLPR Polymorphism Affects Insulin Secretion in Patients with Polycystic Ovary Syndrome. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-7.	1.5	77
35	Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. <i>BMC Endocrine Disorders</i> , 2017, 17, 5.	2.2	54
36	Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β -cell function and insulin sensitivity in metformin treated PCOS. <i>Endocrine Research</i> , 2017, 42, 261-268.	1.2	21

#	ARTICLE	IF	CITATIONS
37	Increased Coagulation and Decreased Fibrinolysis as Measured with Overall Hemostatic Potential Are Dependent on BMI and Not Associated with PCOS. <i>Metabolic Syndrome and Related Disorders</i> , 2017, 15, 194-198.	1.3	6
38	Low serum testosterone is associated with impaired graft function early after heart transplantation. <i>Clinical Transplantation</i> , 2017, 31, e12970.	1.6	4
39	Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study. <i>Metabolic Syndrome and Related Disorders</i> , 2017, 15, 515-520.	1.3	23
40	<i>SORCS1</i> polymorphism and insulin secretion in obese women with polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2016, 32, 395-398.	1.7	6
41	Efficacy of CD34+ Stem Cell Therapy in Nonischemic Dilated Cardiomyopathy Is Absent in Patients With Diabetes but Preserved in Patients With Insulin Resistance. <i>Stem Cells Translational Medicine</i> , 2016, 5, 632-638.	3.3	33
42	A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. <i>Hormones</i> , 2015, 14, 81-90.	1.9	67
43	Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 817-824.	1.9	49
44	Optimal scan time for evaluation of parathyroid adenoma with [¹⁸ F]-fluorocholine PET/CT. <i>Radiology and Oncology</i> , 2015, 49, 327-333.	1.7	44
45	Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. <i>Journal of Ovarian Research</i> , 2015, 8, 32.	3.0	55
46	Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome. <i>Endocrine Research</i> , 2015, 40, 133-138.	1.2	60
47	Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. <i>European Journal of Endocrinology</i> , 2014, 170, 451-459.	3.7	119
48	Phosphodiesterase 4 Inhibition as a Potential New Therapeutic Target in Obese Women With Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1476-E1481.	3.6	37
49	Dihydratachysterol intoxication treated with pamidronate: a case report. <i>Cases Journal</i> , 2010, 3, 78.	0.4	10
50	Assessment of insulin resistance in young women with polycystic ovary syndrome. <i>International Journal of Gynecology and Obstetrics</i> , 2008, 102, 137-140.	2.3	31
51	Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome.. <i>European Journal of Endocrinology</i> , 2008, 158, 793-801.	3.7	37
52	Decreased Androgen Levels and Improved Menstrual Pattern after Angiotensin II Receptor Antagonist Telmisartan Treatment in Four Hypertensive Patients with Polycystic Ovary Syndrome: Case Series. <i>Croatian Medical Journal</i> , 2007, 48, 864-870.	0.7	18
53	SARS-CoV-2 Omicron symptoms and adverse effects of GLP-1 RA therapy. <i>Acta Diabetologica</i> , 0, , .	2.5	0
54	Genetic variability in the cholecystokinin A receptor affects lipid profile and glucose tolerance in patients with polycystic ovary syndrome. <i>Archives of Medical Science</i> , 0, , .	0.9	0